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Introduction
Juvenile idiopathic arthritis (JIA) therapy in the youngest
patients (pts) is particularly difficult. Etanercept (ETA)
and adalimumab (ADA) are approved for use in moder-
ate and severe JIA in pts older than 2 years, but avail-
able data about treatment in the youngest children are
limited.
Objectives
The aim of study was the evaluation of the effectiveness
of TNF inhibitors in pts with JIA who had started ther-
apy before the age of five.
Methods
13 children aged 2 to 5 years with polyarticular JIA - 2
or extended oligoarticular JIA -11 pts (according to the
ILAR criteria) treated with anty-TNF were included in
the study (2007-20013). All pts at the start of anti-TNF
treatment received two synthetic modified drugs
(including methotrexate) and glucocorticoids (GC), in
10 pts intraarticular GC injections were used. The
assessment of clinical effectiveness included JIA out-
come parameters (PhGA, PaGA, CHAQ, ESR/CRP,
number of joints with active arthritis; number of joints
with limited range of motion), JADAS 71 scale and
American College of Rheumatology pediatric (PedACR)
30/50/70/90 responses. Disease activity was measured at
the baseline and every 6 months.
Results
In all (13) pts the first used biological drug was ETA.
The treatment of ETA was started in a mean 2,46 year
± 1,2 months of disease. The mean duration of therapy
with ETA was 24 ± 11,81 months. At 6 months of ETA
treatment 85% of pts achieved PedACR30, high PedACR
50/70/90 responses were achieved in 61% pts. In 8 pts
ETA treatment was terminated after at least 18 months
remission on the drug (according to the Polish thera-
peutic program). 4 of them developed a disease exacer-
bation in mean 3,25 months after the termination of
ETA and the treatment was restarted. 2 children (15%)
did not respond satisfactorily and they were switched to
ADA and at least PedACR 30 response was achieved. In
11 children the treatment of GC was terminated. In all
patients the treatment with anti-TNF was well tolerated.
No deaths, malignancies or opportunistic infections
were reported.
Conclusion
In the youngest children with JIA, TNF inhibitor ther-
apy is well tolerated and effective. In case of active dis-
ease it is necessary to switch to another biological agent.
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